Contribution of KRAS mutations and c.2369C > T (p.T790M) EGFR to acquired resistance to EGFR-TKIs in EGFR mutant NSCLC: a study on circulating tumor DNA

INTRODUCTION: KRAS oncogene mutations ((MUT)KRAS) drive resistance to EGFR inhibition by providing alternative signaling as demonstrated in colo-rectal cancer. In non-small cell lung cancer (NSCLC), the efficacy of treatment with EGFR tyrosine kinase inhibitors (EGFR-TKIs) depends on activating EGFR...

Volledige beschrijving

Bewaard in:
Bibliografische gegevens
Gepubliceerd in:Oncotarget
Hoofdauteurs: Del Re, Marzia, Tiseo, Marcello, Bordi, Paola, D'Incecco, Armida, Camerini, Andrea, Petrini, Iacopo, Lucchesi, Maurizio, Inno, Alessandro, Spada, Daniele, Vasile, Enrico, Citi, Valentina, Malpeli, Giorgio, Testa, Enrica, Gori, Stefania, Falcone, Alfredo, Amoroso, Domenico, Chella, Antonio, Cappuzzo, Federico, Ardizzoni, Andrea, Scarpa, Aldo, Danesi, Romano
Formaat: Artigo
Taal:Inglês
Gepubliceerd in: Impact Journals LLC 2016
Onderwerpen:
Research Paper
Online toegang:https://ncbi.nlm.nih.gov/pmc/articles/PMC5355124/
https://ncbi.nlm.nih.gov/pubmed/26799287
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.18632/oncotarget.6957
Tags: Voeg label toe
Geen labels, Wees de eerste die dit record labelt!

Gelijkaardige items